Back to journals
Academic JournalOpen Access

Therapeutic Advances in Psychopharmacology

22 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 22 psychedelic papers Blossom tracks from Therapeutic Advances in Psychopharmacology line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Therapeutic Advances in Psychopharmacology carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

4papers published in 2021

+33% vs 2020

15 published by 2021

Browse papers→

Don't read as the journal's total output: only the 22 of 22 tracked psychedelic papers from Therapeutic Advances in Psychopharmacology with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Therapeutic Advances in Psychopharmacology publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
18
Anxiety Disorders
13
Safety & Risk Management
9
Addiction & Substance Use
7
Bipolar Disorder
5
PTSD
3
Schizophrenia
3
Creativity
3
Other
18

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Therapeutic Advances in Psychopharmacology cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

LSD
6
Psilocybin
6
Ketamine
6
Ayahuasca
3
Esketamine
2
MDMA
1
DMT
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Therapeutic Advances in Psychopharmacology has 22 tracked papers indexed in Blossom (2013–2026) from 113 authors, most often covering LSD, Psilocybin and Ketamine, across Depressive Disorders, Anxiety Disorders and Safety & Risk Management.

Published Papers

Open Accessindividual

Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians

This survey study (n=41) examined how Swiss physicians provide psychedelic-assisted therapy under legal exemptions, mainly for depression, anxiety, PTSD and chronic pain. It found wide variation in practice, with psilocybin, MDMA and LSD commonly used, music often played during sessions, and adverse effects usually including disorientation, feeling cold, anxiety and nausea.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Beichmann, K., Catzeflis, P., Aicher, H. D., Seragnoli, F., Calder, A., Amrani, A., Hasler, G.
Open Accessindividual

Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study

This observational study (n=45) followed people with treatment-resistant depression for up to 5 years and found that adjunctive intranasal esketamine was linked with sustained reductions in depression scores in those who stayed on treatment. No hypomania or mania was seen, and side effects were generally low.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Cuomo, A., McIntyre, R., Koukouna, D., Pinzi, M., Pardossi, S., Firenzuoli, B., Barillà, G., Carmellini, P., Alamia, A., Fagiolini, A.
Open Accessmeta

Psychedelic therapy and postpartum depression: priorities and prospects

This review (2026) considers serotonergic psychedelic therapy as a potential treatment for postpartum depression, highlighting early encouraging findings but stressing that its efficacy and safety are not yet established. It also examines the biological pathways involved in postpartum depression and calls for tailored, long-term studies that account for the unique needs and risks of the postpartum period.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Thuery, G., Crossen, F., Mc Loone, D., Hinds, C., Duffy, R., Jairaj, C., Harkin, A., Kelly, J. R.
Open Accessindividual

What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial

In an open‑label 8‑week pilot trial, thematic analysis of interviews with 17 people with major depressive disorder found that many participants reported enhanced self‑determination, increased connectedness, clearer cognitive processing and improved emotional well‑being that they linked to reduced depressive symptoms. However, responses were heterogeneous—some reported negative effects or no benefit—and the open‑label design without a placebo control limits causal conclusions and emphasises the need for careful dosing and realistic expectations.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Joy Donegan, C., Daldegan-Bueno, D., Sumner, R. L., Forsyth, A., Evans, W., Hoeh, N. R., Sundram, F., Menkes, D., Muthukumaraswamy, S., Reynolds, L.
Open Accessindividual

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

An open‑label pilot trial of two 25 mg psilocybin sessions with preparatory and integration psychotherapy for treatment‑resistant depression produced a clinically meaningful reduction in self‑rated depressive symptoms at three weeks (Hedges’ g = −1.27) that was maintained at 20 weeks, although individual responses varied (two sustained responders, three relapses, two non‑responders). Exploratory analyses linked pre‑dosing mindset, spiritual experiences and perceptual shifts to outcome trajectories, with adverse events consistent with prior studies and no serious adverse events.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Meikle, S., Carter, O., Liknaitzky, P., Johansen, L., Iyer, R., Strauss, N., Williams, M., Castle, D., Rossell, S. L., Ids, O.
Open Accessmeta

History repeating: guidelines to address common problems in psychedelic science

The paper identifies ten key methodological and inferential challenges in contemporary psychedelic research that undermine internal, external, construct and statistical validity and often co‑occur, casting doubt on claims about efficacy and safety. It groups these problems by ease of resolution and provides a roadmap and practical checklist for researchers, journalists, funders and policymakers to improve rigour and better assess whether current optimism about therapeutic potential is warranted.

Published
Journal
Therapeutic Advances in Psychopharmacology
Authors
Van Elk, M., Fried, E. I.

Quick Facts

Papers Indexed
22
h-Index
46
Open Access
Yes
Publisher
SAGE Publications
Country
United Kingdom
Website
Visit